Abstract
The proliferative component of chronic myelomonocytic leukemia, related to an increased sensitivity of myeloid progenitors to granulocyte macrophage-colony stimulating factor, suggests dedicated therapeutic approaches. In this issue, ruxolitinib, a JAK1 and -2 inhibitory drug, is shown to induce objective responses in chronic myelomonocytic leukemia patients. Clin Cancer Res; 22(15); 3707-9. ©2016 AACRSee related article by Padron et al., p. 3746.
©2016 American Association for Cancer Research.
MeSH terms
-
Antinematodal Agents / therapeutic use*
-
Granulocyte-Macrophage Colony-Stimulating Factor / metabolism*
-
Humans
-
Janus Kinases / metabolism*
-
Leukemia, Myelomonocytic, Chronic / drug therapy*
-
Leukemia, Myelomonocytic, Chronic / metabolism*
-
Nitriles
-
Pyrazoles / therapeutic use*
-
Pyrimidines
-
STAT Transcription Factors / metabolism*
-
Signal Transduction / drug effects
-
Treatment Outcome
Substances
-
Antinematodal Agents
-
Nitriles
-
Pyrazoles
-
Pyrimidines
-
STAT Transcription Factors
-
ruxolitinib
-
Granulocyte-Macrophage Colony-Stimulating Factor
-
Janus Kinases